Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn's disease

被引：0
|
作者：
Wang, Z. [1 ]
Verstockt, B. [2 ,3 ]
Vermeire, S. [2 ,3 ]
Sabino, J. [2 ,3 ]
Ferrante, M. [2 ,3 ]
Declerck, P. [1 ]
Dreesen, E. [1 ,4 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
[3] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.431
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P307
引用
收藏
页码：S335 / S336
页数：4
相关论文
共 50 条
  • [1] Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn's disease
    Dreesen, E.
    Berends, S.
    Laharie, D.
    D'Haens, G.
    Vermeire, S.
    Gils, A.
    Mathot, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S052 - S053
  • [2] Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
    Dreesen, Erwin
    Berends, Sophie
    Laharie, David
    D'Haens, Geert
    Vermeire, Severine
    Gils, Ann
    Mathot, Ron
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (01) : 106 - 118
  • [3] Histological activity in Crohn's disease: Relationship with clinical indices, endoscopic activity and faecal calprotectin
    Buisson, A.
    Mak, W. Y.
    Andersen, M. J., Jr.
    Lei, D.
    Pekow, J.
    Cohen, R. D.
    Pereira, B.
    Setia, N.
    Weber, C.
    Hart, J.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S179 - S180
  • [4] HISTOLOGICAL ACTIVITY IN CROHN'S DISEASE: RELATIONSHIP WITH CLINICAL INDICES, ENDOSCOPIC ACTIVITY AND FAECAL CALPROTECTIN
    Buisson, Anthony
    Mak, Wing Yan
    Andersen, Michael J.
    Lei, Donald
    Pekow, Joel R.
    Cohen, Russell D.
    Pereira, Bruno
    Setia, Namrata
    Weber, Christopher R.
    Hart, John A.
    Rubin, David T.
    GASTROENTEROLOGY, 2018, 154 (06) : S592 - S593
  • [5] Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications
    Le Tilly, Olivier
    Bejan-Angoulvant, Theodora
    Paintaud, Gilles
    Ternant, David
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (03) : 1594 - 1595
  • [6] Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
    Battat, Robert
    Kopylov, Uri
    Bessissow, Talat
    Bitton, Alain
    Cohen, Albert
    Jain, Anjali
    Martel, Myriam
    Seidman, Ernest
    Afif, Waqqas
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (09) : 1427 - +
  • [7] Faecal calprotectin combined with faecal lactoferrin in predicting the endoscopic outcomes of patients with moderate-to-severe Crohn's disease receiving infliximab: a pilot study
    Wu, J.
    Huang, W.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S470 - S471
  • [8] ANALYSIS OF EXPOSURE-OUTCOMES OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Yao, Jiayin
    Zhang, Min
    Liu, Tao
    Zhi, Min
    GUT, 2021, 70 : A103 - A103
  • [9] Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy
    Turvill, James
    FRONTLINE GASTROENTEROLOGY, 2014, 5 (03) : 167 - 175
  • [10] A faecal microbial signature, in combination with faecal calprotectin, to optimise endoscopic activity monitoring in Crohn's Disease
    Taboada-Lopez, S.
    Malagon, M.
    Amoedo, J.
    Ramio-Pujol, S.
    Busquets, D.
    Bahi, A.
    Gilabert, P.
    Rodriguez-Alonso, L.
    Manosa, M.
    Canete, F.
    Torres, P. F.
    Morales, V. J.
    Delgado-Guillena, P. G.
    Domenech, E.
    Guardiola, J.
    Serra-Pages, M.
    Garcia-Gil, L. J.
    Aldeguer, X.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2142 - I2142
12345